ABSI Absci Corporation

QT59

Latest market price

10.05

+0.36+3.72%

Overview Short InterestFilings

ABSIQT59Absci Corporation·NASDAQ

Overview Short InterestFilings

10.05+3.72%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

URGN+0.28%$34.45 MAZE+5.61%$32.08 NTLA+1.63%$11.85 GENB+4.99%$13.87 STOK+2.48%$27.14 TRAX+2.30%$46.09 NUVB+0.76%$4.63 RARE+2.94%$16.78

Snapshot

Index	—	P/E	—	EPS (ttm)	-0.94	Insider Own	30.43%	Shs Outstand	171.61M	Perf Week	2.54%

Market Cap	1.66B	Forward P/E	—	EPS next Y	-0.73	Insider Trans	0.10%	Shs Float	148.14M	Perf Month	-12.47%

Enterprise Value	1.46B	PEG	—	EPS next Q	-0.19			Short Float	24.99%	Perf Quarter	14.27%

Income	-115.00M	P/S	—	EPS this Y	—			Short Ratio	10.98	Perf Half Y	72.42%

Sales	3.00M	P/B	6.76	EPS next Y	—	ROA	-45.02%	Short Interest	37.02M	Perf YTD	177.65%

Book/sh	1.43	P/C	8.27	EPS next 5Y	—	ROE	-59.21%	52W High	12.54 -19.86%	Perf Year	136.92%

Cash/sh	1.17	P/FCF	—	EPS past 3/5Y	—	ROIC	-52.24%	52W Low	2.24 348.66%	Perf 3Y	742.61%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	-20.63% -9.71%	Gross Margin	-255.93%	Volatility	12.37% 9.74%	Perf 5Y	-18.02%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	-8411.27%	ATR (14)	1.00	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	10.63	Sales Y/Y TTM	-80.00%	Profit Margin	-7756.37%	RSI (14)	48.76	Recom	2.23

Dividend Gr. 3/5Y	—	Current Ratio	10.63	EPS Q/Q	25.00%	SMA20	-0.23%	Beta	2.15	Target Price	13.67

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-100.00%	SMA50	1.90%	Rel Volume	1.04	Prev Close	9.69

Employees	140	LT Debt/Eq	0.01	Earnings	Nov 12	SMA200	48.56%	Avg Volume	3.63M	Price	10.05

IPO Date	Jul 22, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.77% -67.38%	Net Debt/EBITDA	—	Volume	3,787,842	Change	3.72%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-29-26	Reiterated	Jefferies		$14
Sep-08-26	Reiterated	BTIG	Buy	$9.00 → $15
Jun-25-26	Reiterated	Morgan Stanley	Overweight	$4.10 → $10
Jun-25-26	Reiterated	HC Wainwright & Co.	Buy	$8.00 → $16
Jun-15-26	Reiterated	Guggenheim	Buy	$15
Jun-04-26	Initiated	Leerink	Outperform	$12
May-28-26	Initiated	BTIG	Buy	$9.00
May-14-26	Reiterated	Morgan Stanley	Overweight	$4.20 → $4.10
Jan-08-26	Reiterated	Morgan Stanley	Overweight	$4.32
Mar-21-24	Reiterated	Stifel Nicolaus		$6.00

Latest News· Times ET

Oct-29-26

Oct-29-2602:26PM

Jefferies Initiates Coverage On Absci with Buy Rating, Announces Price Target of $14Benzinga

Oct-27-26

Oct-27-2608:00AM

Absci to Participate in Upcoming Investor Conferencesglobenewswire.com

Oct-16-26

Oct-16-2607:11PM

Absci (ABSI) Stock Seems Rich Against Its Book Value BackdropYahoo

Oct-13-26

Oct-13-2608:00AM

Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026globenewswire.com

Oct-08-26

Oct-08-2604:15AM

Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)defenseworld.net

Oct-07-26

Oct-07-2607:17PM

Absci (ABSI) Stock Dropped, So What Is Behind The Latest Attention?Yahoo

Sep-29-26

Sep-29-2603:30AM

Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical ProgressSeekingAlpha

Sep-24-26

Sep-24-2608:00AM

Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosisglobenewswire.com

Sep-21-26

Sep-21-2606:15AM

Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrastdefenseworld.net

02:45AM

Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN)defenseworld.net

Sep-17-26

Sep-17-2607:58AM

Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On ThursdayBenzinga

Sep-16-26

Sep-16-2603:51PM

Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

Sep-09-26

Sep-09-2609:07AM

Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add UpSeekingAlpha

Sep-08-26

Sep-08-2603:51PM

Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)seekingalpha.com

Sep-04-26

Sep-04-2603:26AM

Absci Corporation $ABSI Shares Bought by Bank of America Corp DEdefenseworld.net

Company

Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	3	5	6	—	—	—	—
Cost of Goods Sold Incl. D&A	12	62	48	—	—	—	—
Gross Profit	-9	-58	-42	—	—	—	—
Selling, General and Administrative Excl. Other	35	0	0	—	—	—	—
Research and Development	81	64	48	—	—	—	—
Other Operating Expense	0	-13	26	—	—	—	—
Operating Income	-125	-109	-116	—	—	—	—
Interest Expense	0	1	1	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—
Non-Operating Income (Expense)	10	6	6	—	—	—	—
Net Income Before Taxes	-115	-103	-110	—	—	—	—
Income Taxes	0	0	0	—	—	—	—
Consolidated Net Income	-115	-103	-111	—	—	—	—
Net Income From Continuing Operations	-115	-103	-111	—	—	—	—
Net Income	-115	-103	-111	—	—	—	—
EPS (Recurring)	-0.84	-0.94	-1.20	—	—	—	—
EPS (Basic, Before Extraordinaries)	-0.84	-0.94	-1.20	—	—	—	—
EPS (Diluted)	-0.84	-0.94	-1.20	—	—	—	—
EBITDA	-103	-94	-80	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—
Price To Sales Ratio	159.38	57.64	64.40	—	—	—	—
Gross Margin	-300.00	-1,160.00	-700.00	—	—	—	—
Operating Margin	-4,166.67	-2,180.00	-1,933.33	—	—	—	—
Net Margin	-3,833.33	-2,060.00	-1,850.00	—	—	—	—
Shares Outstanding	137	110	92	—	—	—	—
Market Capitalization	478	288	386	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Szela Mary T	Director	Jun 30 '26	Buy	11.54	12,900	148,866	21,300	Jul 06
Pangalos Menelas N	Director	May 13 '26	Buy	5.36	37,453	200,748	232,308	May 13
Busch Andreas	Chief Innovation Officer	Mar 12 '26	Buy	2.29	100,000	229,000	421,446	Mar 16
Pangalos Menelas N	Director	Feb 27 '26	Buy	2.74	75,095	205,760	189,055	Mar 03
McClain Sean	Chief Executive Officer	Feb 23 '26	Option Exercise	1.21	396,399	479,643	8,730,966	Feb 25
Jonasson Zachariah	CFO / CBO	Feb 02 '26	Sale	2.99	17,496	52,313	383,538	Feb 04
McClain Sean	Chief Executive Officer	Feb 02 '26	Sale	2.99	26,761	80,015	8,334,567	Feb 04
VAN HOUTEN FRANS	Director	Dec 05 '25	Buy	3.72	40,000	148,800	63,320	Dec 09
Pangalos Menelas N	Director	Sep 22 '25	Buy	2.66	95,785	254,788	113,960	Sep 24
Bedrick Todd	SVP, CAO	Sep 22 '25	Buy	2.70	10,000	27,000	180,428	Sep 24
Busch Andreas	Chief Innovation Officer	Jul 28 '25	Buy	3.04	50,000	152,000	327,264	Jul 29
Jonasson Zachariah	CFO / CBO	Jun 13 '24	Sale	4.98	19,859	98,892	384,751	Jun 14
Jonasson Zachariah	CFO / CBO	Jun 13 '24	Option Exercise	3.39	28,700	97,293	404,610	Jun 14
Phoenix Venture Partners II LP	10% Owner	May 22 '24	Sale	4.40	3,100,000	13,640,000	11,279,522	May 28
Redmile Group, LLC	Director	Mar 01 '24	Buy	4.50	222,222	999,999	8,253,316	Mar 05

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.